Drugs / Allogeneic γδ T (ABOUT) cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07144735 | Apr 2025 → Dec 2027 expected | glioblastoma | Peking University Third Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic γδ T (ABOUT) cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144735 ↗ |
| Action | Inhibit | “genetically edited to knockout the ARIH1 and BCL11b genes” NCT07144735 ↗ |
| Modality | Cell therapy | “Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.” NCT07144735 ↗ |
| Target | ARIH1 | “Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.” NCT07144735 ↗ |
| Target | BCL11B | “Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.” NCT07144735 ↗ |